Biotechnology Assets S.A. is a biotechnology company that develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industry sectors in Spain and internationally. It specializes in innovative technologies such as SPLITTERA, a universal and robust solution for site-specific conjugation of proteins, alongside a portfolio including CLICK-N-CUT, CLICK-VLP, CLICK-CAR, VACC-ZERA platform, and CLICK-BIO for drug delivery, enabling technologies, diagnostics, and preclinical services. The company operates through subsidiaries like Biobide, which provides zebrafish-based toxicity and efficacy testing; ZIP Solutions, offering intein-based tools for gene therapy, immunotherapy, in vitro diagnostics, vaccines, and protein purification; and Bionatur, focusing on assets for human and animal health, including licensing of biotech platforms, preclinical research, and vaccine improvements. Biotechnology Assets S.A. supports areas such as biodrugs, in vitro diagnostics, vaccines, genetic and rare diseases, infectious diseases, immunology, animal health, and professional services like CRO and CMO. Founded in 1954 and headquartered in Cádiz, Spain, it plays a key role in advancing health, agrifood, and industrial biotechnology solutions.